NCT07698535 Docetaxel Metastatic Castration-Resistant Prostate Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07698535—Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07698535 is a hot trial to watch

Metastatic Castration-Resistant Prostate Cancer is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07698535 is notable because it tests Docetaxel, Lutetium (177 Lu) Vipivotide Tetraxetan in a Phase 2 design with Number and proportion among those recruited with detectable circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction who undergo randomization as a primary decision variable. The wider PatSnap topic query returned 540 trial records and 1,801 result records, so differentiation depends on evidence quality rather than activity alone.

PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Number and proportion among those recruited with detectable circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction who undergo randomization—determines what uncertainty this study can resolve. The reported time frame is Up to 2 cycles (Cycle length = 6 weeks). Enrollment of 64 participants and geography in United States shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

Benchmark readouts in the same clinical field

• Role of CAR-T cell therapy in prostate cancer: A systematic review and meta-analysis. (Not Applicable): CRS(≥Grade 3) = 9.2 % .
• Sequencing of PARP inhibitors and taxane chemotherapy in HRR-altered metastatic castration-resistant prostate cancer: A real-world VA analysis. (Not Applicable): OS: HR = 1.09(95.0% CI, 0.84 - 1.41); HR = 0.9(95.0% CI, 0.41 - 1.85); OS: HR = 1.09(95.0% CI, 0.84 - 1.41); HR = 0.9(95.0% CI, 0.41 - 1.85); OS: HR = 1.09(95.0% CI, 0.84 - 1.41); HR = 0.9(95.0% CI, 0.41 - 1.85); OS: HR = 1.09(95.0% CI, 0.84 - 1.41); HR = 0.9(95.0% CI, 0.41 - 1.85).
• Evaluation of the safety, efficacy and dosimetry of TRC003 in metastatic castration-resistant prostate cancer: A prospective, open-label, single-arm study. (Phase 1): AE = The most common AE was anemia (80%) and dry mouth (73.3%). ; AE = The most common AE was anemia (80%) and dry mouth (73.3%). .

These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Docetaxel (Approved; Tubulin); Lutetium (177 Lu) Vipivotide Tetraxetan (Approved; PSMA).

Company & Deal Intelligence context: University of Washington — http://www.washington.edu.

The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

1. Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
2. Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
3. Sequencing evidence: randomized data after the most relevant contemporary standard of care.
4. Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
5. Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07698535 is a focused lens on Metastatic Castration-Resistant Prostate Cancer development. Its value will be determined by whether Docetaxel can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.